Investors Hub Daily
|
Home
|
Log in
Boards
Stocks
Commodities
Forex
The Lounge
Hot!
Breakout Boards
iHub My Stocks Activity
Ticker Buzz Cloud
Top Boards
Most Read
Most Posted
Most Followed Members
Recent News
Active Boards
Site Stats
New Boards
Hot on StockWiki
Data Tools
Charts
Trader Alerts
Trades
Portfolio
Top Lists
News Alerts
Commodities
More Tools
My Image Gallery
Advanced Search
Videos
All News
Stock Screener
News Filter
Live Charts
Live News
Live Desktop
Forex Prices
Commodities
ETF Center
Online Brokers
Educational Channel
Streamer
Level 2
Home
>
Boards
>
Free Zone
>
All Trading - Technical
>
ORIONS Portfolio Money Making Stocks
$CPRX This week expect good results of CPP-115
Public Reply
|
Private Reply
|
Keep
|
Last Read
Post New Msg
Next 10
|
Previous
|
Next
TraderUsa
Tuesday, July 24, 2012 3:13:41 PM
Re:
None
Post #
of
255909
$CPRX This week expect good results of CPP-115 and go to $2...
What is CPP-115?
CPP-115 is one of a group of novel GABA aminotransferase inhibitors and derivatives of vigabatrin discovered by Northwestern University. CPP-115, an analog of CPP-109, is being developed by Catalyst under the patents licensed from Northwestern in August 2009. Read about Catalyst's licenses here.
CPP-115 has two potentially significant advantages compared to CPP-109. First, CPP-115 may not cause the visual field defects associated with chronic administration of vigabatrin and second, CPP-115 has been shown to be at least 200 times more potent than CPP-109 in both in vitro and animal model studies. The increased potency could enable the development of superior or alternative dosage forms and routes of administration. Catalyst hopes that these important benefits will allow it to develop not only next-generation addiction products, but a broad range of other central nervous system therapies, beginning with epilepsy and pain management.
In 2011, Catalyst advanced the development of CPP-115 by commencing a randomized, double-blind, single ascending dose Phase I(a) study in six cohorts of eight normal healthy volunteers to evaluate the human safety characteristics of CPP-115, including CNS side effects and respiratory and cardiovascular safety.
SOURCE:
http://www.catalystpharma.com/cpp115.htm
Is my humble opinion.
Do not forget to go through this ihub :
http://investorshub.advfn.com/boards/board.aspx?board_id=20991
$$
DEVALUED STOCKS
$$
Public Reply
|
Private Reply
|
Keep
|
Last Read
Post New Msg
Next 10
|
Previous
|
Next
Follow Board
Keyboard Shortcuts
Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote
-
Discussion Board
+/- to Watchlist
© 2013 InvestorsHub.Com, Inc.